BONE MARROW TRANSPLANTATION

Scope & Guideline

Fostering Global Dialogue in Bone Marrow Advancements.

Introduction

Explore the comprehensive scope of BONE MARROW TRANSPLANTATION through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore BONE MARROW TRANSPLANTATION in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0268-3369
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1986 to 2024
AbbreviationBONE MARROW TRANSPL / Bone Marrow Transplant.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'BONE MARROW TRANSPLANTATION' focuses on the latest advancements and research findings in the field of hematopoietic stem cell transplantation (HSCT) and related cellular therapies. It encompasses a wide range of studies, from clinical trials to epidemiological analyses, aiming to improve the understanding and treatment of hematological malignancies and other disorders through transplantation.
  1. Hematopoietic Stem Cell Transplantation (HSCT):
    The journal emphasizes research on the efficacy, safety, and outcomes of HSCT for various hematological disorders, including leukemia, lymphoma, and myelodysplastic syndromes. This encompasses studies on conditioning regimens, donor selection, and post-transplant care.
  2. Graft-versus-Host Disease (GVHD):
    A significant part of the journal's focus is on the prevention, diagnosis, and treatment of GVHD, a common complication following HSCT. This includes exploring novel prophylactic strategies and therapies for managing acute and chronic GVHD.
  3. Innovative Therapies and Techniques:
    Research on novel cellular therapies such as CAR-T cell therapy, as well as advancements in immunotherapy and targeted therapies, is frequently published, reflecting the journal's commitment to integrating new treatment modalities into clinical practice.
  4. Infectious Complications and Management:
    The journal addresses the challenges of infectious complications in HSCT recipients, including the management of viral reactivations (e.g., CMV, EBV) and bacterial infections, highlighting the importance of prophylactic strategies and treatment protocols.
  5. Patient-Centered Care and Quality of Life:
    Studies examining the psychosocial aspects, quality of life, and long-term outcomes of patients undergoing HSCT are also a critical focus, emphasizing the holistic approach to patient care.
The journal reflects ongoing advancements and shifts in research focus, with several emerging themes gaining attention. These trends indicate the evolving landscape of hematopoietic stem cell transplantation and associated therapies.
  1. Post-Transplant Cyclophosphamide (PTCy):
    There is a growing body of research dedicated to the use of PTCy as a prophylactic treatment in haploidentical stem cell transplantation, highlighting its effectiveness in reducing GVHD and improving transplant outcomes.
  2. CAR-T Cell Therapy:
    The ongoing exploration of CAR-T cell therapy in various hematological malignancies, particularly in relapsed or refractory cases, is a prominent theme, showcasing its integration into transplantation protocols.
  3. Patient Engagement and Quality of Life Research:
    An increasing focus on patient-reported outcomes and quality of life in HSCT recipients signifies a shift towards more patient-centered research, emphasizing the importance of psychosocial factors in treatment success.
  4. Microbiome Research in Transplantation:
    Emerging studies investigating the role of gut microbiota in transplant outcomes and GVHD are gaining traction, reflecting a broader interest in the interplay between microbiome health and patient recovery.
  5. Use of Advanced Imaging and Biomarkers:
    The integration of advanced imaging techniques and biomarker research to predict outcomes post-transplantation is becoming more common, enhancing the ability to tailor treatments to individual patient needs.

Declining or Waning

While 'BONE MARROW TRANSPLANTATION' continues to evolve, certain themes and areas of research are witnessing a decline in prominence. This may reflect shifts in clinical priorities, emerging treatments, or changes in the scientific landscape.
  1. Traditional Conditioning Regimens:
    There is a noticeable decrease in studies focused solely on traditional myeloablative conditioning regimens as researchers increasingly explore reduced-intensity and non-myeloablative approaches, which are becoming more favored in practice.
  2. Single Donor Transplantation Studies:
    Research focusing on single donor transplantation models, particularly in less diverse donor settings, is becoming less common as the field shifts towards exploring haploidentical and mismatched donor strategies, which are gaining traction.
  3. Basic Science Studies on Stem Cell Biology:
    There seems to be a waning interest in basic science research solely focused on stem cell biology without direct clinical applications, as more research is geared towards translational studies and clinical outcomes.
  4. Longitudinal Studies with Limited Sample Sizes:
    The frequency of longitudinal studies with small sample sizes appears to be decreasing, as there is a growing emphasis on larger, multicenter studies that offer more robust data and generalizable findings.

Similar Journals

Experimental Hematology & Oncology

Unveiling Innovations in Cancer and Hematological Science
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Turkish Journal of Hematology

Empowering the global hematology community through open access.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

AMERICAN JOURNAL OF HEMATOLOGY

Pioneering Insights for Tomorrow's Hematology
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Blood Science

Advancing Hematology Through Innovative Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

ACTA HAEMATOLOGICA

Advancing Hematological Knowledge for a Healthier Tomorrow
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

Iraqi Journal of Hematology

Shaping the Future of Hematological Practices
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Innovating treatment pathways for young patients.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

Current Research in Translational Medicine

Driving Progress in Biochemistry, Hematology, and Beyond
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 2452-3186Frequency: 4 issues/year

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

Hematology-American Society of Hematology Education Program

Exploring Innovations in Hematological Science
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Hematologie

Connecting Researchers and Clinicians in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.